5 FDA decisions to watch in the third quarter
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Iveric Zimura. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Astellas Pharma agreed to acquire Iveric Bio for approximately $5.9 billion, in a deal designed to expand the buyer’s eye treatment pipeline.